Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer (Q24200413)

21 October 2023

Tiago B de Castria

1

Tiago B

de Castria

1 reference

21 October 2023

Edina MK da Silva

series ordinal

2

author given names

Edina M K

author last names

da Silva

1 reference

21 October 2023

Aecio FT Gois

series ordinal

3

author given names

Aecio F T

author last names

Gois

1 reference

Cochrane Database of Systematic Reviews

21 October 2023

language of work or name

1 reference

16 August 2013

0 references

published in

0 references

cites work

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009256.PUB2

Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009256.PUB2

Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009256.PUB2

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009256.PUB2

Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma .

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009256.PUB2

Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009256.PUB2

Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009256.PUB2

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009256.PUB2

Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009256.PUB2

Grey literature in meta-analyses of randomized trials of health care interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009256.PUB2

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009256.PUB2

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009256.PUB2

Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009256.PUB2

A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009256.PUB2

Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009256.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009256.PUB2

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009256.PUB2

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009256.PUB2

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009256.PUB2

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009256.PUB2

Estimation of glomerular filtration rate in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009256.PUB2

American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009256.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/14651858.CD009256.PUB2

0 references

Fatcat ID

release_zfg5thyv75apfbnmp4ufgmjgeq

0 references